WASHINGTON/ BEIJING, Aug 28- The chairman of China's Tsinghua Unigroup travelled to the United States this week to meet with board members of Micron Technology and try to revive a politically fraught takeover bid of the U.S. chipmaker, people familiar with the matter said. Senator Charles Schumer of New York called on the inter-agency Committee on Foreign...» Read More
Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.
Pfizer is working on its next move in a potential $100 billion battle for AstraZeneca after having two bids rejected. CNBC's Meg Tirrell reports buying AstraZeneca would boost Pfizer's cancer drug pipeline.
The "Squawk on the Street" team weigh in on Pfizer's bid to takeover European drug maker AstraZeneca.
CNBC's Dominic Chu provides a timeline of Bill Ackman's stake in Allergan.
Activist investor Carl Icahn comments on Bill Ackman's role in the Valeant Pharmaceuticals bid for Allergan. The "Squawk on the Street" team provide insight.
The "Squawk on the Street" news team discuss the involvement of Bill Ackman in the deal between Valeant Pharmaceuticals and Allergan.
William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.
Sandy Villere, Villere Funds, shares his thoughts on Greenlight Capital's new stake in Conn's.
CNBC's Meg Tirrell digs into the friendly and hostile M&A action taking place in pharmaceuticals, including a deal between Novartis and GlaxoSmithKline, and Valeant Pharmaceuticals bid for Allergan.
Valeant Pharmaceuticals offered $48.30 share cash, as well as 0.83 shares for Allergan. CNBC's Meg Tirrell provides insight.
In an SEC Filing, Valeant Pharmaceuticals said it expected to offer a mix of stock and about $15 billion in cash for botox maker Allergan. David Krempa, Morningstar equity analyst, and CNBC's Meg Tirrell, provide perspective.
Activism in the long-term is not only bad for shareholders but also bad for the economy as a whole, says Martin Lipton, Wachtell, Lipton, Rosen & Katz, expressing his views on shareholder activism. Also Lipton shares his thoughts on the two categories of hedge fund activism.
Eileen Nugent, Skadden, Arps, Slate, Meagher & Flom, and Robert Spatt, , Simpson Thacher & Bartlett, discuss go-shop deals in the M&A environment and the latest LBO buzz from New Orleans.
Sam Zell, Equity Group Investments chairman, shares his thoughts on the strength of the U.S. economy. We have to focus on growth, says Zell. James Bullard, Federal Reserve Bank of St. Louis president and CEO, weighs in.
Sam Zell, Equity Group Investments chairman, discusses backing an activist campaign to unseat the board and management of CommonWeath, a real estate investment trust that owns more than 300 office buildings.
CNBC's Scott Wapner reports Dan Loeb's Third Point will nominate three members to Sotheby's board of directors including Loeb himself.